Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 694 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief... June 8, 2021 Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients... August 14, 2024 Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... July 11, 2022 Load more HOT NEWS ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... Reflections from the World Cancer Congress Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared...
